About 15 months after ending development of a different hereditary angioedema candidate due to liver safety worries, KalVista Pharmaceuticals, Inc. reported what analysts called best-case scenario results for its Phase III oral kallikrein inhibitor sebetralstat (KVD900) on 13 February. With the data in hand, KalVista said it plans to file sebetralstat for on-demand therapy in HAE by midyear, with expectations that it might become a foundational treatment for the rare swelling disorder.
KalVista Plans Quick FDA Filing After Phase III Success In On-Demand HAE Therapy
The firm’s oral kallikrein inhibitor might offer a better overall profile for on-demand treatment than currently approved therapeutic and prophylactic agents, analysts said.
More from Clinical Trials
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.